Evolving use of new oral anticoagulants for treatment of venous thromboembolism.

  title={Evolving use of new oral anticoagulants for treatment of venous thromboembolism.},
  author={Calvin H. Yeh and Peter L. Gross and Jeffrey I Weitz},
  volume={124 7},
The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of the majority of patients with venous thromboembolism (VTE). With a rapid onset of action and the capacity to be administered in fixed doses without routine coagulation monitoring, NOACs streamline VTE treatment. In phase 3 trials in patients with acute symptomatic VTE, NOACs have been shown to be noninferior to conventional anticoagulant therapy for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 31 extracted citations


Publications referenced by this paper.
Showing 1-10 of 44 references

The epidemiology of venous thromboembolism. Circulation

  • RH White
  • 2003
Highly Influential
7 Excerpts

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis

  • T van der Hulle, J Kooiman, PL den Exter, OM Dekkers, FA Klok, MV. Huisman
  • J Thromb Haemost
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…